At 12 mg, 100% of participants lost at least 5% of body weight and 83% lost at least 15%
There is very little evidence on the effectiveness of injections, says Mandavia
TRIUMPH-1 (80 Weeks) The pivotal TRIUMPH-1 obesity trial (2,339 adults, no diabetes), presented at ADA 2026, extended the treatment window to 80 weeks and produced the largest pivotal weight-loss readout to date: Among the 12 mg group, 45.3% lost at least 30% of their body weight and 65.3% ended the trial with a BMI below 30
Tirzepatide, marketed as Zepbound for weight management, has shown higher average weight loss than semaglutide in many trial comparisons
"All of these things go together, and our goal is not only to make people smaller but also to make people healthier and stronger, which is so powerful." As more people explore the use of GLP-1 medicines -- KFF said about a third of adults had heard a lot about the drugs -- it will be integral for providers to practice holistic patient engagement and chronic disease management with their patients
Some GLP-1s have shown promise for reducing alcohol consumption in animal and human studies
